Thank you day traders!
The more relevant question is whether you think CLSN will appreciate in price sitting at a market cap of only $50 million. Regardless of whether trials prove successful or not, do you think in 2014 CLSN price will perhaps double or more? History says yes.
I don't understand your point. DNDN went from $4 to $50 then back down to $4. Hopefully CLSN can repeat that performance.
With close to $50 million in cash, reverse split completed, financing secured, patents regarding Thermodox, CLSN at a market cap of $50 million is grossly undervalued. This may turn out to be a multibagger in 2014 as enrollment in PIII trials commences. I may get in here for the inevitable climb.
Good job holding on and now flipping your entire position as I did. I am hoping for a pullback in the $3.75 range. I keep upping it every week! It was $2.75, then $3.00. Oh well. I will be back for sure. If it crosses $5 it is on its way to $10. I will join again at $5.00.
These guys are all jokers and slime. The past few months all they were talking about is OREX as a winner, pumping up the stock, upgrading the stock for anticipated 100 million offering. Too funny and oh so predictable!
This can easily become the next ACAD. $2 to $20 in a flash. Here's hoping for a pullback. Already sold naked puts on this the past 7 days lowering my entry point.
Missed out the run from $3 to $4. No one ever went broke taking a profit but who would have guessed this move to $4.40? Wow. Impressive. GALE has become a daytrader's dream now. It will attract a lot of attention now and every dip will be met with significant buying. Institutional interest has risen as well.
I must revise my entry points from $3.00 to $3.75 on down. Barring an unexpected PIII trial outcome, I do not see GALE returning to the $2 range any time soon.
ARNA will never see those levels again. But thank you so so much. I really mean it!
Please remind me to thank you once ARNA returns to $8 in short short order. Thank you shorts!
Have a look at my previous post regarding Pfizer and Eisai long term ongoing relationship and what it means for Arena.
ARNA price action exactly mimics that of HGSI and as we all know, HGSI is history.
With the recent action and whales moving into Arena as of late, I had to raise this point once again. I cannot emphasize enough how the recent Arena action with the price falling from $8 to $4 then violently back up matches that of HGSI. It is identical people. No covered calls for me. No trading shares any more.
This is exactly why Pfizer will make a move for Arena and Eisai. With $34 billion in cash, Pfizer has no choice but to invest in its future.
This is becoming more of a reality with the recent price action. Pfizer and Eisai have always been very very chummy. It is inevitable that Pfizer acquire both Eisai and Arena together.
Exactly! Focus of weekly scripts is a loser's game for shorts. It has become much greater than weekly scripts. It has become all about milestone payments and licensing out technology to big pharma partners with deep pockets and huge infrastructure.
I can't wait for ARNA to go after ACAD for patent infringement. ;)
For short sales on stocks which are deemed "hard to borrow", there may be interest-like fees (known in the industry as "negative rebates") associated with carrying the short position. This interest will accrue from settlement date of the short sale until settlement date of the buy-to-cover. The charge will levied on or about the 20th of the month. The formula for the interest calculation will be: (Market Value x Rate x # of days) / 360.
For ARNA, I get 10% to loan out my shares, shorts pay about 30%.
For GALE, I get 30% to loan out my shares, shorts pay about 50%.
How is being short either stock profitable in the long run? Simple. It is not. Can't squeeze blood out of a turnip.
If I am getting 10% to loan out my shares, shorts are paying at least 30% interest to hold onto their short positions.
We will realize a market cap of $2.25B or $10.25 per share very shortly. Whales are scooping up chunks of Arena shares. All this action from $8 to $4 was an attempt to defraud retail investors out of their shares. Why? Because Arena will no longer dilute with $250 million in cash with no debt. No chance of shares being created out of thin air.
This is great action we are seeing! Finally Jack reached out to institutes and possibly Wall Street and painted a very rosy picture of ARNA's prospects with Belviq and pipeline hence large block buys that only whales can pull off.
It is the hell that shorts have created for themselves. Welcome to the beginning of the end.